On October 26, 2018 Allergan plc (NYSE: AGN) reported that its Board of Directors has declared a cash dividend of $0.72 per ordinary share for the fourth quarter of 2018 (Press release, Allergan, OCT 26, 2018, View Source [SID1234530200]). The dividend will be paid on December 14, 2018 to shareholders of record at the close of business on November 13, 2018

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On October 26, 2018 PharmaMar (MSE:PHM) has reported that the Phase III ATLANTIS trial has received from the Independent Data Monitoring Committee (IDMC) its recommendation that the trial, currently under way with Zepsyre (lurbinectedin, PM1183) in combination with doxorubicin in relapsed small-cell lung cancer patients should continue without any changes. This is the fourth IDMC safety data review that has been passed.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The IDMC’s recommendation came after having reached the targeted number of 600 patients recruited.

The ATLANTIS trial compares Lurbinectedin plus doxorubicin to physician’s choice of either Topotecan or CAV (cyclophosphamide, adriamycin, vincristine) in a 1 to 1 randomization. The primary endpoint is overall survival, and based on the expected number of events, the results are expected around the end of 2019. The trial is 90% powered to deliver a hazard ratio of 0.75.

Legal warning
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

On October 26, 2018 Tiziana Life Sciences plc (AIM: TILS), a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, reported that it has raised US$1,500,000 by the issue of 1,515,150 new ordinary shares ("Placing Shares") at a price of US$0.99 (75p) per share at a fixed exchange rate of GBP 1 : US$ 1.32 (the "Placing") (Press release, Tiziana Life Sciences, OCT 26, 2018, View Source [SID1234530137]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Application will be made to London Stock Exchange plc to admit the Placing Shares to trading on AIM ("Admission") with Admission expected to occur on or around 19 November 2018. The Placing Shares will rank pari passu with the existing ordinary shares of nominal value 3 pence each in the capital of the Company (the "Ordinary Shares").

Following Admission, the fully diluted issued share capital of the Company will consist of 151,790,735 Ordinary Shares (assuming all options and warrants, vested and unvested, exercised and exercisable, were converted).

Total Voting Rights

In conformity with DTR 5.6.1, the Company notifies that as at the date of this announcement, it has a single class of shares in issue being Ordinary Shares and that following the issue of the Placing Shares, the total number of Ordinary Shares in issue will be 128,442,449. There are no Ordinary Shares held in treasury. Each Ordinary Share entitles the holder to a single vote at general meetings of the Company.

The figure of 128,442,449 Ordinary Shares may be used by shareholders (and others with notification obligations) as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Company under the FCA’s Disclosure Guidance and Transparency Rules.

The person who arranged for release of this announcement on behalf of the Company was Tiziano Lazzaretti, Chief Financial Officer of Tiziana.

On October 26, 2018 XBiotech Inc. (NASDAQ: XBIT) announced today that it was awarded 11 new patents or patent allowances in the third quarter of 2018. Patents issued relate to the Company’s drug candidates bermekimab and 514G3, which target a crucial mediator of chronic inflammation and Staphylococcus aureus (including MRSA), respectively (Press release, XBiotech, OCT 26, 2018, View Source;p=RssLanding&cat=news&id=2373711 [SID1234530155]). The new patents include those issued from European authorities to protect bermekimab when used in the treatment of dermatological pathologies and cancer-associated cachexia. Patent allowances include one each in Australia, Canada, Israel, Mexico, the Philippines, Russia, and South Korea that include covering: bermekimab in the treatment of cardiovascular disease; the 514G3 antibody to treat Staphylococcus aureus infections; and key aspects of the Company’s True HumanTM antibody discovery platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Stanley Kim, Ph.D., J.D., XBiotech’s Corporate Vice President of Intellectual Property, stated, "These recently issued patents reflect XBiotech’s efforts to develop significant worldwide protection for its emerging candidate therapies. The Company’s patent portfolio currently includes over 100 issued patents."

XBiotech’s substantial patent portfolio supports a diverse drug development platform. The Company is currently conducting clinical research with bermekimab as a combination therapy to treat pancreatic cancer. In addition, ongoing evaluation of results from XBiotech’s colorectal cancer programs continues to be conducted to investigate patient response to bermekimab and to further direct the Company’s oncology program. XBiotech has two separate dermatological clinical trials underway investigating response to bermekimab in patients with atopic dermatitis and hidradenitis suppurativa. Both studies are expected to be completed this year or by first quarter 2019. The Company is also currently exploring possibilities of conducting further clinical studies with 514G3 to prevent and treat Staphylococcus aureus infections, as well as bermekimab to prevent and treat cardiovascular disease. XBiotech continues to advance its pipeline for other infectious disease indications, including Clostridium difficile and varicella zoster virus (shingles).

About True Human Therapeutic Antibodies
XBiotech’s True Human antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech’s True Human antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability.

On October 25, 2018 Corcept Therapeutics Incorporated (NASDAQ: CORT) reported it will report its third quarter 2018 financial results and provide a corporate update on November 1, 2018 (Press release, Corcept Therapeutics, OCT 25, 2018, https://ir.corcept.com/news-releases/news-release-details/corcept-therapeutics-announce-third-quarter-financial-results-2 [SID1234530685]). The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call Information

To participate, dial 1-877-260-1479 from the United States or 1-334-323-0522 internationally approximately 10 minutes before the start of the call. The passcode is 7489528.

A replay will be available through November 15, 2018 at 1-888-203-1112 from the United States and 1-719-457-0820 internationally. The passcode will be 7489528.